Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Choose from Insulin Cartridge stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Plans and pricing Video Back Videos home Signature ...

Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA) for weight loss and weight management in people with obesity or overweight and a weight-related health condition. It ...

Plastic, prefilled insulin pens are an option that makes diabetes management and daily insulin injections easier to manage. These do not eliminate the need to use a needle for injecting insulin ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

MONTREAL, May 27, 2025 /CNW/ - – Bristol Myers Squibb Canada (BMS) today announced that Health Canada has approved OPDIVO ® SC (nivolumab for subcutaneous injection) across all currently ...

Different types of injections include intravenous, intramuscular, subcutaneous, intraosseous, and intradermal. A healthcare professional can use injections, or shots, to administer vaccines and ...

It is the first subcutaneous injection for this condition. The treatment was approved by the Medicines and Healthcare products Regulatory Agency last month. Marstacimab is administered weekly.

(MENAFN- Quintile Reports) The Global Smart Insulin Pens & Pumps Market was estimated at USD 8.36 billion in 2025 and is projected to reach USD 15.13 billion by 2034 , reflecting a robust CAGR of ...

The new devices – NovoPen 6 and NovoPen Echo Plus – are insulin self-injection pens that record information such as when and how much insulin is administered, with the data uploaded to an app ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

Medicare will pay the remaining 80% of the insulin pump’s cost. Note, however, that Part B does cover the insulin you need to use with the pump, but it doesn’t cover insulin pens or supplies ...